Sava is scaling its next-gen CGM across Europe. What’s happening: The UK-based biosensor developer raised $36M in a Series B led by Ascensia Diabetes Care to speed its affordable continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results